1. Introduction {#sec1}
===============

Lung cancer is the most common cause of death from cancer worldwide with a bleak overall 5-year survival rate of less than 15% for all-comers \[[@B1]\]. For treatment purposes, lung cancer is divided into two major subgroups, small cell (SCLC) and non-small-cell lung cancer (NSCLC). NSCLC accounts for approximately 80% of all lung cancers and is further divided into three major histological subtypes, which are adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma \[[@B1], [@B2]\]. NSCLC is often diagnosed at an advanced stage when the prognosis is poor, resulting in low survival rates despite recent improvements in treatments \[[@B3]\]. Detection of accurate biomarkers can prognosticate cancer correctly with an aim to improve overall survival (OS). There is increasing evidence to suggest that micro-ribonucleic acids (miRNAs) play a critical role in the development of NSCLC and have been proposed as potential biomarkers for NSCLC prognosis and response to therapy \[[@B3], [@B4]\].

miRNAs are small (\~22 nucleotides) noncoding RNAs that regulate more than half of the genes in human cells and are associated with various biological activities including cell proliferation, cell differentiation, cell migration, disease initiation, disease progression, and apoptosis \[[@B5]\]. miRNAs modulate gene activity at the posttranscriptional level by degrading or inhibiting the translation of their messenger RNA (mRNA) targets. It has been observed that miRNAs expression is frequently upregulated for oncogenic miRNA and downregulated for tumor suppressor miRNA \[[@B6]\].

Many investigators have carried out miRNA profiling studies in NSCLC with cell lines, paired tissue samples, and blood samples. Microarray-based miRNA profiling assays are robust methods of screening hundreds of miRNAs. Given a large number of potential candidate miRNAs, well-established miRNA signatures documented in the literature have been identified \[[@B4], [@B7]--[@B11]\]. In collating the results and verifying miRNA profile platforms, a major challenge is normalization and determining significant thresholds.

A pooled analysis of multiple miRNA expression profile studies for NSCLC patients was performed to explore the association between miRNA expressions and OS. The starting point of this meta-analysis was to collect various published miRNA profiling studies comparing microRNA expressions in NSCLC patients and correlating high expression levels compared to low expression profiles against OS. By extracting summary statistics from these studies for survival endpoints, we analysed the predictive value of miRNA-148a (miR-148a), miRNA-148b (miR-148b), miRNA-let-7 (*Let*-7), miRNA-21 (miR-21), and miRNA-155 (miR-155) for NSCLC prognosis.

2. Materials and Methods {#sec2}
========================

This meta-analysis was performed following the guidelines of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement \[[@B12]\].

2.1. Search Strategy {#sec2.1}
--------------------

The scientific literature published from January 2004 to March 2017 was interrogated using 5 different search engines: Scopus, PubMed, Science Direct, Web of Science, and Medline using key search words, including "microRNA expression or miRNA expression," "lung cancer or NSCLC," "prognosis," "radiotherapy," "radioresistance," "radiosensitivity," and "Human" (Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}). A manual review of references from published articles was also performed to select some additional studies.

2.2. Study Selection {#sec2.2}
--------------------

PubMed search engine was selected as it provided the most relevant literature search for this topic. We reviewed all titles, including abstracts and full texts and ensured adherence to the inclusion and exclusion criteria for the meta-analysis. The primary literature that contained expression profiles of various miRNAs with multivariate analysis (high vs. low) and information including OS, HRs, 95% CIs, and *P* values were included in this meta-analysis. Moreover, included studies were also required to report on clinicopathological and demographic data associated with the patient\'s samples. Studies were excluded if they did not describe the association between miRNA expression and OS. Articles without full text or written in a language other than English were also excluded. Any doubt or uncertainty regarding the quality and inclusion of a piece of research work was resolved with the consensus of two clinical oncologists.

2.3. Quality Assessment {#sec2.3}
-----------------------

Two reviewers critically assessed the quality of all the studies included in this meta-analysis. All the studies were categorised into three groups: "unsatisfactory," "satisfactory," and "good" quality. The cut-off score was designed so that each study needed to be above "satisfactory" as described in [Table 1](#tab1){ref-type="table"}.

2.4. Data Extraction {#sec2.4}
--------------------

We independently extracted the required information from all eligible studies for meta-analysis. Prespecified data parameters included: Demographic data regarding population, ethnicity, and survival rates during follow-upTumor data (histology, stage, primary lesions, and lymphoid node invasion)Experimental data involving study design, materials, assays, and dysregulation of miRNAs expressionStatistical data including HRs for OS, 95% CI, and *P* valuePublication data (author\'s name, publication year, and journal title)

2.5. Statistical Analysis {#sec2.5}
-------------------------

HRs and 95% CIs extracted from the graphical survival plots from eligible articles were combined for the OS results. Forest plots were used to illustrate the association of miRNAs expression and OS. Heterogeneity was assessed using the Cochran Q test and Higgins I-squared statistic. *P* value less than 0.05 (*P* \< 0.05) and I-squared value greater than 50% (I-square \> 50%) indicated the presence of significant heterogeneity across studies. The random effect model was applied in the presence of heterogeneity between studies. An observed HR \> 1 indicated a worse OS and poor prognosis in the group with elevated or reduced miRNA expressions. Publication bias was evaluated with the inverted funnel plot and the Egger\'s and Begg\'s bias indicator test. All the *P* values were two-sided, with *P* value less than 0.05 (*P* \< 0.05) considered statistically significant. All calculations were performed using Comprehensive Meta-Analysis Version 3.0 software (Biostat, USA).

3. Results {#sec3}
==========

3.1. Literature Search and Study Characteristics {#sec3.1}
------------------------------------------------

A preliminary online PubMed search highlighted a total of 578 studies concerning miRNA expression and lung cancer prognosis. An additional 26 studies were included from references and citations within the primary highlighted articles. Total 559 records were excluded as they represented irrelevant studies to the current analysis, review articles, letters, and *in vitro/in vivo* studies. Based on the readings of the article titles and abstracts and according to the inclusion and exclusion criteria, 45 articles were selected for more detailed evaluation. An additional 18 articles were excluded as they lacked key statistics in which eight articles did not mention HR or 95% CI values, whereas ten articles did not report on OS of the selected miRNAs. Finally, a total of 27 articles consisting of 32 independent studies were included in the meta-analysis. A flow chart of the study selection process is shown in [Figure 1](#fig1){ref-type="fig"}. Three articles \[[@B13]--[@B15]\] included two independent cohorts each, whereas one article \[[@B16]\] included three independent cohorts.

The data from the 32 studies included in the meta-analysis is summarized in [Table 2](#tab2){ref-type="table"}. There was a total of 5553 samples from all of the studies, which was sorted according to country: United States (1439), Europe (662), and Asia (3452). Most Asian patient samples were from China (81.55%). Twenty-eight retrospective studies included tissue samples while four prospective studies used liquid biopsy samples \[[@B13], [@B17], [@B18]\]. miRNA expression levels were predominantly studied in paired tumor tissues, i.e., cancer tissue and adjacent benign tissue (20 out of 28 studies) as eight tissue sample studies made no mention if patient samples were paired tissue samples or single tumor biopsies. Among all 28 tissue sample studies, 12 studies included all tumor subtypes, whereas eight studies included only adenocarcinoma, four studies included only squamous cell carcinoma, and four studies \[[@B13], [@B19]--[@B21]\] did not differentiate the tumor subtype.

All 32 studies reported the prognostic value of 21 different miRNAs explaining OS. The upregulated and downregulated miRNAs reported in all studies are listed in [Table 3](#tab3){ref-type="table"}. Twenty-eight studies reported on tumors at various stages of clinical presentation, whereas this information was absent in seven studies \[[@B13]--[@B15], [@B20], [@B21]\]. *In situ* hybridization (ISH) was utilized in four studies \[[@B15], [@B22], [@B23]\], while miRNA array and quantitative real-time PCR (qRT-PCR) remained the predominant techniques for miRNA detection in the remaining studies.

3.2. Study Outcomes {#sec3.2}
-------------------

All the included articles reported a close relationship between miRNAs and lung cancer prognosis. Among the 21 reported miRNAs, increased expression of miR-21, miR-155, miR-662, miR-708, miR-31, and miR-146b and decreased expression of miR-148a, miR-29c, miR-200a, miR-148b, miR-383, miR-153, miR-375, miR-155, miR-181a, and miR-*let*-7 were found associated with poor survival in NSCLC. Five miRNAs (miR-21, miR-155, miR-*let*-7, miR-148a, and miR-148b) were reported in at least two studies and provided all the key data to perform subgroup meta-analysis. The HRs and 95% CIs extracted from the studies were combined to interrogate the relationship between miRNA expression and lung cancer prognosis. The combined results revealed that both high and low expression levels of the listed miRNAs were associated with a poor prognosis in NSCLC, with a combined HR \> 1.5. The combined HR (95% CI) for all 32 studies was calculated as 1.59 (1.39--1.82; *P* \< 0.001), indicating a high level of heterogeneity (I-squared = 84.97%, *P* \< 0.001). For all the data showing high heterogeneity, random effects model was applied ([Figure 2](#fig2){ref-type="fig"}).

3.3. Subgroup Analysis {#sec3.3}
----------------------

Considering the heterogeneity among the studies, the effect of miRNA expression was further evaluated by subgroup analysis. The subgroups were classified according to the repeated miRNAs on the studies, which are the source of those miRNAs, miRNA assay methods, analysis type, and patient origin ([Table 4](#tab4){ref-type="table"}). The association between miRNA expressions and OS outcome was statistically significant in most of the subgroups analysis including miRNA sources, sample origin, miRNA assay by qRT-PCR (HR = 1.05, 95% CI 0.58--1.87, *P* \< 0.001), and univariate and multivariate analysis (HR = 2.29, 95% CI 1.02--5.12, *P* = 0.043 and HR = 1.54, 95% CI 1.35--1.76, *P* \< 0.001, respectively) except ISH assay method (HR = 1.05, 95% CI 0.58--1.87, *P* = 0.870).

For all 20 studies using the paired tissue samples as patient\'s sample, the random effect model pooled HR for OS was calculated as 1.67 (95% CI: 1.39--1.99, *P* \> 0.001), suggesting significant heterogeneity among the studies. Moreover, significant publication bias observed (Egger\'s test, *P* = 0.0001) among the included studies. High miRNA expression levels were observed in tumor tissues compared to normal adjacent tissue. The overexpression of miR-21 \[[@B16], [@B19], [@B20], [@B24]--[@B27]\], miR-155 \[[@B15], [@B16], [@B20], [@B28], [@B29]\], miR-662 \[[@B30]\], miR-708 \[[@B14]\], miR-31 \[[@B31]\], and miR-146b \[[@B28]\] predicted poor OS despite the cancer site. As eight studies did not specify if the patient\'s samples were taken as paired tissue sample or just single cancer tissue samples, these were excluded from paired tissue sample subgroup. Four studies targeted serum or plasma miRNAs, where both lower and higher expression levels of miRNAs were found associated with poor survival as well, with the combined HR 1.73 (95% CI: 1.13--2.65, *P* = 0.012). No apparent bias was observed (Egger\'s test, *P* = 0.151) among the studies.

Another subgroup analysis was performed for the location of sample collection to explore the cause of the heterogeneity between studies. The Asian and European subgroups exhibited greater heterogeneity (I-squared, *P* values approximately 78.85%, \<0.001 and 61.28%, 0.006, respectively) compared to the American subgroup (I-squared: 0.00% and *P* value: 0.946). However, no significant publication bias was observed in the Asian and European studies (Egger\'s test, *P* = 0.125 and *P* = 0.397, respectively) compared to the American studies (Egger\'s test, *P* = 0.023). Overall, higher expression levels of miRNAs (miR-21, miR-155, miR-662, and miR-31) and lower expression levels of miRNAs (miR-148a, miR-29c, miR-200a, miR-148b, miR-181a, miR-153, miR-383, miR-375, and miR-*let*-7) reflected poorer prognosis. Particularly, the high expression level of miR-21, miR-155, miR-708, and miR-146b were correlated with poor overall survival in American studies.

Five miRNAs (miR-21, miR-155, miR-*let*-7, miR-148a, and miR-148b) were reported in at least two studies and were specifically analysed under subgroup analysis to evaluate the association between miRNA expression and overall survival in NSCLC.

### 3.3.1. miR-21 Expression in NSCLC Prognosis {#sec3.3.1}

Eight articles (*n* = 2025) reported the effect of miRNA-21 on the prognosis of NSCLC patients ([Figure 2(g)](#fig2){ref-type="fig"}). Of these studies, seven provided overall survival data and one provided relapse-free survival data \[[@B16]\]. Evident heterogeneity was detected among all the studies (I-square = 88.05%, *P* \< 0.001), suggesting the presence of other contributing factors. Overall, the random-effects model revealed that miRNA-21 expression was inversely associated with OS (HR: 1.95; 95% CI: 1.40--2.72; *P* \< 0.001) in NSCLC patients. However, the asymmetry test (OS, Egger test, *P* = 0.227) indicated the existence of symmetry in the funnel plot which indicated no apparent bias in the studies included in the meta-analysis.

### 3.3.2. miR-155 Expression in NSCLC Prognosis {#sec3.3.2}

[Figure 2(h)](#fig2){ref-type="fig"} displays the forest plot representation for the analysis of miRNA-155 and OS. Six articles (*n* = 2047) with nine individual cohort studies were subjected to the analysis. The random effect model was used to calculate the pooled effect size due to the presence of prominent heterogeneity among studies (I-square = 73.27%, *P* \< 0.001). Elevated miRNA-155 expression was identified as a moderate predictor of poor OS regardless of the source of miRNAs. The pooled HR for OS was calculated as 1.33 (95% CI: 0.87--2.04, *P* = 0.176), suggesting no statistical significance. Even though significant interstudy heterogeneity was observed, the Egger test result indicated the presence of no significant publication bias (*P* = 0.242) among the studies.

### 3.3.3. miR-*let*-7 Expression and NSCLC Prognosis {#sec3.3.3}

Four studies (*n* = 1239) evaluated the association between miR-*let*-7 expression in the tumor tissue samples and the prognosis of NSCLC patients, with two reporting OS \[[@B20], [@B21]\] and the other two with postoperative survivals \[[@B29], [@B32]\]. The adjusted HR was calculated as 1.94 (95% CI: 0.87--4.32) using random-effect model, suggesting prominent heterogeneity (I-square = 87.59%, *P* \< 0.001). Moreover, significant publication bias observed among these selected studies (Egger\'s test, *P* = 0.010). The calculated high HR value concluded that downregulation of miR-*let*-7 in tumor tissue was associated with poor overall survival of the NSCLC patients among those studies.

### 3.3.4. miRNA-148a and NSCLC Prognosis {#sec3.3.4}

Two studies (*n* = 377) suggested that low miRNA-148a expression levels were associated with poor survival in the patients with NSCLC \[[@B22], [@B33]\]. Evident interstudy heterogeneity was observed across these studies (I-square = 57.92%, *P* = 0.123). The pooled HR for OS was calculated as 2.33 (95% CI: 0.80--6.71, *P* = 0.117), suggesting a significant impact of miR-148a downregulation on the OS in NSCLC patients.

### 3.3.5. miRNA-148b and NSCLC Prognosis {#sec3.3.5}

Two studies (*n* = 380) reported lower miR-148b expression as a predictor for poor OS in NSCLC patients using multivariate analysis \[[@B34], [@B35]\]. No significant heterogeneity was observed across these studies (OS, I-square = 0.00%, *P* = 0.749). Our analysis also revealed that the low miR-148b expression is associated with a significant poor prognosis. The pooled HR for OS was calculated as 2.28 (95% CI: 1.64--3.17, *P* \< 0.001).

3.4. Publication Bias {#sec3.4}
---------------------

Finally, publication bias of the included studies was assessed by a Begg\'s funnel plot and Egger\'s test ([Figure 3](#fig3){ref-type="fig"}). The result of both Begg\'s test (*P* = 0.009) and Egger\'s test (*P* = 0.007) provided the statistical evidence of funnel plot asymmetry concluding apparent bias in the studies included in the meta-analysis.

3.5. Sensitivity Analysis {#sec3.5}
-------------------------

Sensitivity analysis was performed to evaluate whether the differences between studies induced instability in the meta-analysis or not. It was performed by sequential omission of individual studies using the fixed-effects model. No particular study was identified that influenced the overall results.

4. Discussion {#sec4}
=============

We conducted a comprehensive systematic literature review to explore the utility of miRNA biomarkers that can be robustly evaluated in predicting prognosis in NSCLC patients. To our knowledge, this is the first extensive meta-analysis undertaken including the wider time frame (January 2004 to March 2017) and a wide range of miRNAs from both paired and liquid biopsy samples, and their subsequent ability to determine NSCLC prognosis. This meta-analysis pooled high-quality global studies concerning various miRNA expressions and cancer prognosis regarding OS.

Although miRNAs studied in the previous studies were found to be positively or negatively associated with prognosis in NSCLC, most of them were presented in separate studies. In our combined analysis, five different miRNAs (miR-21, miR-155, miR-*let*-7, miR-148a, and miR-148b) were evaluated in at least two selected studies using key statistics and OS data. We performed a subgroup meta-analysis of the effect of these five miRNAs on the survival of NSCLC patients as well. The meta-analysis results suggested that an elevated expression of miR-21 (*P* \< 0.001) and miR-155 (*P* = 0.176) in cancerous tissue and liquid biopsy samples were associated with poor survival, whereas lower expression of miR-*let-*7 (*P* = 0.101) and miR-148a/b (*P* = 0.117 and *P* \< 0.001) also predicted shorter postoperative and overall survival among the NSCLC studies \[[@B15]--[@B22], [@B24]--[@B29], [@B32]--[@B35]\].

The studies that used OS as a primary endpoint had high heterogeneity. This issue of heterogeneity was addressed in this study by performing a subgroup analysis. The OS, consolidated HR, and 95% CI were statistically significant in most of the studies, indicating that overexpression or underexpression of any of these miRNAs may result in a poor prognosis for NSCLC patients. Subgroup analysis based on geography revealed that the studies from America (USA) produced statistically not significant results compared to equivalent studies from Europe and Asia. These findings can conclude that miRNA expression is associated with a poorer prognosis in Asian and European NSCLC population.

Since the initial association of miR-21 with cancer in 2005, it is now considered one of the most extensively explored cancer-related miRNAs \[[@B36], [@B37]\] and may serve as a key regulator in oncogenic processes including tumor growth, migration, and invasion \[[@B38]\]. A growing body of evidence further supports miR-21 as a potential diagnostic and prognostic biomarker in various carcinomas \[[@B7]\]. Moreover, elevated miR-21 expression levels have been found associated with disease-free survival outcomes in cancer patients \[[@B8]\]. However, a meta-analysis by Ma et al., \[[@B9]\] including eight articles found no prognostic significance of miRNA-21 expression in NSCLC. Moreover, a cohort study by Voortman \[[@B20]\] using a large number of participants found neither predictive nor prognostic significance with miR-21 expression patterns, however, significantly associated with the age and tumor stage of the NSCLC patient\'s in OS. In addition, a study by Olivieri et al. \[[@B10]\] suggested that miRNA-21 and miRNA-155 are also upregulated in a normal person without cancer and can be associated with inflammation and senescence. Hence, there are conflicting reports as to the benefit of miR-21 as a prognostic biomarker in cancer. However, a series of recent quantitative analysis based on published studies did, in fact, suggest a significant association between high miR-21 expression levels and poor survival in NSCLC patients \[[@B8], [@B16], [@B19], [@B24]--[@B27], [@B39]--[@B41]\]. This meta-analysis study also supported those previous results, with the pooled effect size calculated by random effect model suggesting high expression levels of miR-21 as a moderate predictor of poor OS (HR: 1.95 and with 95% CI: 1.40--2.72) in NSCLC patients.

Evidences show that miR-155 is overexpressed in various solid tumors, including breast, lung, colon, pancreatic, and thyroid \[[@B7], [@B11], [@B42]\], and also plays a positive role in the development of a tumor \[[@B43]\]. Several studies suggest promising associations between elevated miR-155 levels and prognosis in NSCLC patients \[[@B11], [@B41], [@B43], [@B44]\]. Our meta-analysis comprised nine independent studies \[[@B17]--[@B19], [@B31], [@B34]\] that described the significant prognostic effect of miR-155 expression on OS among NSCLC patients, except Voortman \[[@B20]\], who suggested no significant association. Our combined result also supported the evidence from most of the previous studies suggesting that the high miR-155 expression is likely to result in unfavourable outcomes in NSCLC patients.

MiR-*let*-7 is considered as a protective miRNA that is downregulated in various cancers including lung cancer \[[@B29], [@B45], [@B46]\]. Previous studies have described that low expression of miR-*let*-7 is significantly associated with a poor prognosis in NSCLC \[[@B21], [@B28], [@B29], [@B32], [@B46], [@B47]\]. Similarly, our study also found an association between low miR-*let*-7 expression levels and a poor prognosis in NSCLC studies.

Additionally, another two downregulated miRNAs (miR-148a and miR-148b) were meta-analysed separately for the first time for NSCLC prognosis. Various studies have described the significant association of miR-148a/b overexpression level to the enhanced OS outcome among NSCLC patients \[[@B22], [@B33]--[@B35], [@B48], [@B49]\]. Less heterogeneity was observed with either of these two miRNAs in our study. The fixed effect model pooled significant HR values for the downregulation of both miRNAs that further suggested a significant prognostic role in NSCLC.

Some limitations must be considered when interpreting the results of this current study. First, the number of studies available was limited. More studies based on the prognostic role are needed to further strengthen these associations. Secondly, significant heterogeneity was observed in some of the studies, likely due to the differences in patient\'s clinicopathological characteristics (ethnicity, nationality, gender, age, tumor stage, and tumor grade) and different assay methods, cut-off values for the miRNA expression levels, sample preparation methods (i.e., paraffin-fixed, formalin-fixed, freshly frozen tumors, or liquid biopsy samples), follow-up durations, and key statistic parameters available. Thirdly, circulating biomarkers are more valuable and reliable than tissue biomarkers as they can be assayed before surgery and monitored throughout the tumor progression. Hence, more liquid biopsy sample-based studies need to be included. Lastly, a significant publication bias among the studies may have influenced the overall outcome. Some miRNAs that were chosen empirically or without clear justification in studies could have led to imprecise outcomes. The number of statistically insignificant studies \[[@B16], [@B20], [@B23], [@B24]\] was 15.6% (5 out of 32) and may have limited the statistical power. Patient age could be another variable that might have contributed towards heterogeneity, as four out of the 32 studies \[[@B16], [@B22], [@B50], [@B51]\] showed significant association of age with OS in NSCLC patients. Therefore, the selection of standardized protocol-based studies may likely improve the quality of such analysis. Even though there were heterogeneity, biases, and other limitations, there is growing evidence for the remarkable potential of miRNAs as prognostic biomarkers in NSCLC. More studies should be undertaken in the future to evaluate the prognostic value of specific miRNAs in serum. Large-scale and standard investigations may provide a better understanding of the mode of action and the miRNA targets, to give further insight into the use of miRNAs in lung cancer prognosis, ultimately leading to greater clinical application outcomes.

5. Conclusions {#sec5}
==============

Several miRNAs are established to play critical roles in the initiation and development of NSCLC by functioning either as oncogenes or as tumor suppressor genes. Global miRNA expressions analysed from tumor specimens and liquid biopsy samples from patients may have a clinical relevance to serve for diagnosis, prognosis, and therapeutic outcomes in NSCLC. Our meta-analysis, representing a quantified synthesis of all published studies suggests that specific miRNA signatures which are up- or downregulated in NSCLC are associated with the poor OS and have potential prognostic and predictive value. However, large-scale standardized protocol-based studies are required to improve the accuracy and reduce the bias.
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###### 

The scientific literature published from January 2004 to March 2017 was interrogated using 5 different search engines: Scopus, PubMed, Science Direct, Web of Science, and Medline using key search words, including "microRNA expression or miRNA expression," "lung cancer or NSCLC," "prognosis," "radiotherapy," "radioresistance," "radiosensitivity," and "Human". Literature search results are noted in Supplementary Table 1.

###### 

Click here for additional data file.

![Flow chart of literature review and study selection process.](DM2018-8309015.001){#fig1}

![Forest plots of the studies that evaluated the hazard ratios of high vs. low miRNA expression. (a) Forest plot of the relationship between various miRNA expression and overall survival (OS) in NSCLC patients included in the meta-analysis. (b) Forest plot of the survival data reported in the studies with paired tissue samples (cancerous and adjacent noncancerous) as the source of miRNAs. (c) Forest plot of the survival data reported in the studies based on liquid biopsy samples as a source of miRNAs. (d) Forest plot of survival data from Asia. (e) Forest plot of survival data from Europe. (f) Forest plot of survival data from America. (g) Forest plot of the relationship between high miRNA-21 expression and overall survival in cancer patients with both random and fixed effects model. (h) Forest plot of the included studies that evaluated the hazard ratio of high miRNA-155 expression vs. low expression. (i) Forest plot of the relationship between lower miRNA-let-7 expression and OS in selected studies. (j) Forest plot of survival data for low miRNA-148a expression. (k) Forest plot of survival data for low miRNA-148b expression and OS in NSCLC studies.](DM2018-8309015.002){#fig2}

![Funnel plots of studies included in the meta-analysis of NSCLC.](DM2018-8309015.003){#fig3}

###### 

Quality Assessment of the selected studies for systemic review and meta-analysis.

  Criteria                  Unsatisfactory                                  Satisfactory                                            Good
  ------------------------- ----------------------------------------------- ------------------------------------------------------- -------------------------------------------
  Sample size               Less than ten samples                           10--100 samples                                         \>100 samples
  Cox regression analysis   Only *P* value is given                         Only multivariate analysis with HR, CI, and *P* value   Both univariate and multivariate analysis
  Survival                  Only DFS                                        OS, DFS                                                 OS, DFS, RFS
  miRNAs regulation         No significant upregulation or downregulation   At least one miRNA upregulated or downregulated         \>1 miRNA upregulated or downregulated
  Total studies             0                                               12                                                      15

DFS: disease-free survival; OS: overall survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval; miRNA: microRNA.

###### 

Main characteristics of the studies included in the meta-analysis.

  Study                                 Population      Study period          Sample number (patient/control)   Source of miRNA   miRNA expressed                                  Cancer type/subtype                           Histological stage                                 miRNA analysis platform   Follow-up
  ------------------------------------- --------------- --------------------- --------------------------------- ----------------- ------------------------------------------------ --------------------------------------------- -------------------------------------------------- ------------------------- ----------------------
  Chen et al., 2017 \[[@B22]\]          China           Jul 2004--Jun 2009    165/165                           Tissue (FFPE)     miR-148a                                         SCC: 45.5%; AC: 54.5%                         T1 = 34; T2 = 89; T3 = 41; U = 1                   ISH                       5 yrs
  Liu et al., 2017 \[[@B52]\]           China           2003--2005            87                                Tissue (FFPE)     miR-29c                                          AC                                            T1 = 10; T2 = 62; T3 = 15                          miRNA array/qRT-PCR       5 yrs
  Chen et al., 2016 \[[@B23]\]          China           Jan 2010--Jun 2012    134                               Tissue (FFPE)     miR-200a                                         SCC: 41.8%; AC: 48.5%; ASC: 5.2%; LCC: 4.5%   T1 = 34; T2: 26; T3a: 74                           ISH                       28 months (1--58)
  Wang et al., 2016 \[[@B34]\]          China           Jan 2014--May 2015    39/39                             Tissue            miR-148b                                         SCC: 38.5%; AC: 61.5%                         T1 = 12; T2, T3 & T4 = 27                          qRT-PCR                   (2--60) months
  Shang et al., 2016 \[[@B53]\]         China           Jun 2009--Sept 2010   139/139                           Tissue            miR-383                                          SCC: 59%; AC: 41%                             T1 & T2 = 63; T3 = 76                              qRT-PCR                   60 months
  Chen et al., 2015 \[[@B50]\]          China           Mar 2007--Apr 2013    137/137                           Tissue            miR-153                                          SCC: 49.6%; AC: 50.4%                         T1 & T2 = 104; T3 & T4 = 33                        qRT-PCR                   5 yrs
  Ge et al., 2015 \[[@B35]\]            China           May 2007--Apr 2012    151/151                           Tissue            miR-148b                                         SCC: 46.4%; AC: 43.7%                         T1 & T2 = 91; T3 & T4 = 60                         qRT-PCR                   N/A
  Skrzypski et al., 2014 \[[@B30]\]     Poland          2001--2012            134                               Tissue            miR-662/miR-192/miR-192^∗^                       SCC                                           T1a = 29; T1b = 65; T2a = 4 & T2b = 31 & T3a = 5   miRNA array/qRT-PCR       5.8 yrs (4.1--10.0)
  Yu et al., 2014 \[[@B13]\]            China           May 2008--Jul 2010    164/164                           Serum             miR-375                                          SCC: 26.8%, AC: 60.98%, Others: 12.2%         T1 = 3; T2 = 42; T3 = 58; T4 = 34                  qRT-PCR                   24 months (0--56)
  53/53                                 Serum           miR-375               N/A                               N/A               qRT-PCR                                          24 months (0--56)                                                                                                          
  Xiao-chun et al., 2013 \[[@B19]\]     China           2001--2007            60/60                             Tissue            miR-21                                           NSCLC                                         T1 & T2 = 29; T3 & T4 = 31                         qRT-PCR                   N/A
  Sanfiorenzo et al., 2013 \[[@B17]\]   France          Mar 2008--Mar 2010    52/20                             Plasma            miR-155                                          SCC: 48%; AC: 52%                             T1a = 8; T1b = 14; T2a = 5; T2b = 8; T3a = 7       qRT-PCR                   N/A
  Chen et al., 2013 \[[@B33]\]          China           Feb 2008--Dec 2009    47                                Tissue (FFPE)     miR-148a                                         SCC: 52.1%; AC: 47.9%                         T1 = 25; T2 & T3 = 23                              qRT-PCR                   N/A
  Jang et al., 2012 \[[@B14]\]          USA             Jan 1997--Sep 2008    56/56                             Tissue (FF)       miR-708                                          AC                                            N/A                                                miRNA array/qRT-PCR       N/A
  47/47                                 Tissue (FFPE)   miR-708               AC                                N/A               miRNA array/qRT-PCR                              N/A                                                                                                                        
  Liu et al., 2012 \[[@B24]\]           China           2003--2005            70/70                             Tissue            miR-21                                           AC                                            T1 = 10; T2 = 62; T3 = 15                          miRNA array/qRT-PCR       2 yrs
  Li et al., 2012 \[[@B51]\]            China           Jan 2006--Dec 2007    96/96                             Tissue            miR-375                                          SCC: 43.75%; AC: 56.25%                       T1 or T2 = 66; T3 = 30                             qRT-PCR                   30 months (8--69)
  Tan et al., 2011 \[[@B31]\]           China           2000--2002            60/60                             Tissue            miR-31                                           NSCLC                                         T1 = 21; T2 = 17 & T3 = 22                         miRNA array/qRT-PCR       N/A
  Donnem et al., 2011 \[[@B15]\]        Norway          1990--2004            191                               Tissue (SCC)      miR-155                                          SCC                                           N/A                                                ISH                       86 months (48--216)
  95                                    Tissue (AC)     miR-155               AC                                N/A               ISH                                              86 months (48--216)                                                                                                        
  Saito et al., 2011 \[[@B16]\]         USA             1987--2009            89/89                             Tissue            miR-21/miR-155                                   AC                                            T1 = 57; t2 = 22; T3 = 10                          qRT-PCR                   5 yrs
  Norway                                1988--2003      37/37                 Tissue                            miR-21/miR-155    AC                                               T1 = 21; T2 = 5; T3 = 11                      qRT-PCR                                            5 yrs                     
  Japan                                 1998--2008      191/191               Tissue                            miR-21/miR-155    AC                                               T1 = 142; T2 = 49                             qRT-PCR                                            5 yrs                     
  Wang et al., 2011 \[[@B18]\]          China           2003--2005            88/17                             Serum             miR-21                                           SCC: 23.9%, AC: 42%, Others: 34.1%            T1, T2 = 47; T3 = 41                               miRNA array/qRT-PCR       52.16 months (1--73)
  Gao et al., 2011 \[[@B25]\]           China           Feb 2004--Jan 2005    30/30                             Tissue            miR-21                                           SCC                                           T1 = 17; T2 = 12 & T3 = 13                         miRNA array/qRT-PCR       4-5 yrs
  Gao et al., 2010 \[[@B26]\]           China           Apr 2008--Sep 2008    47/47                             Tissue            miR-21/miR-181a                                  SCC: 55.32%; AC: 44.68%                       T1 = 22; T2 = 12 & T3 = 13                         miRNA array/qRT-PCR       N/A
  Voortman et al., 2010 \[[@B20]\]      USA             N/A                   697/79                            Tissue            miR-155/miR-21/miR-*let-7/*miR-29b/miR-34a/b/c   NSCLC                                         N/A                                                qRT-PCR                   8 yrs
  Raponi et al., 2009 \[[@B28]\]        USA             Oct 1991--Jul 2002    61/10                             Tissue            miR-155/mir-146b                                 SCC                                           T1: 33; T2--T4 = 28                                qRT-PCR                   3 yrs
  Markou et al., 2008 \[[@B27]\]        Greece          2004--2005            48/48                             Tissue            miR-21                                           SCC: 47.9%; AC: 52.1%                         T1 & T2 = 32; T3 & T4 = 16                         qRT-PCR                   39 months
  Yu et al., 2008 \[[@B21]\]            Taiwan          Sept 2000--Dec 2003   112                               Tissue            miR-*let*-7                                      N/A                                           N/A                                                miRNA array/qRT-PCR       N/A
  Yanaihara et al., 2006 \[[@B29]\]     USA             N/A                   104/104                           Tissue            miR-*let*-7/miR-155                              SCC: 37.5%; AC: 62.5%                         T1 = 65; T2 = 17; T3 & T4 = 22                     qRT-PCR                   N/A
  Takamizawa et al., 2004 \[[@B32]\]    Japan           N/A                   143                               Tissue            miR-*let*-7                                      SCC: 17.5%; AC: 73.4%; LCC: 6.3%; ASC: 2.8%   T1 = 71; T2 = 19 & T3 = 49                         qRT-PCR                   N/A

FF: formalin-fixed; FFPE: formalin-fixed paraffin-embedded; AC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large-cell carcinoma; ASC: adeno-squamous carcinoma; NSCLC: non-small-cell lung carcinoma; qRT-PCR: quantitative real time PCR; N/A: not available.

###### 

MicroRNA regulation (upregulated and downregulated) reported from the selected studies.

  Consistently reported upregulated and downregulated miRNAs in selected studies                                                                                                                      
  -------------------------------------------------------------------------------- ---------------------------------------------- ------ ------------- ---------------------------------------------- ------
  miR-21                                                                           8 \[[@B16], [@B18]--[@B20], [@B24]--[@B27]\]   1871   miR-*let*-7   5 \[[@B18], [@B20], [@B21], [@B29], [@B32]\]   1445
  miR-155                                                                          6 \[[@B15]--[@B17], [@B20], [@B28], [@B29]\]   2176   miR-30a       4 \[[@B14], [@B25], [@B26], [@B31]\]           380
  miR-182                                                                          5 \[[@B14], [@B18], [@B21], [@B28], [@B31]\]   709    miR-126       4 \[[@B25], [@B26], [@B28], [@B29]\]           433
  miR-210                                                                          4 \[[@B14], [@B28], [@B29], [@B31]\]           605    miR-181a      3 \[[@B18], [@B25], [@B26]\]                   242
  miR-31                                                                           4 \[[@B14], [@B25], [@B26], [@B31]\]           480    miR-143       3 \[[@B25], [@B26], [@B29]\]                   362
  miR-191                                                                          3 \[[@B17], [@B28], [@B29]\]                   383    miR-486-5p    2 \[[@B14], [@B31]\]                           226
  miR-205                                                                          3 \[[@B18], [@B27], [@B29]\]                   392    miR-375       2 \[[@B13], [@B51]\]                           313
  miR-200a                                                                         2 \[[@B23], [@B28]\]                           339    miR-148a      2 \[[@B22], [@B33]\]                           426
  miR-412                                                                          2 \[[@B25], [@B26]\]                           154    miR-34b       2 \[[@B14], [@B20]\]                           845
  miR-135b                                                                         2 \[[@B14], [@B26]\]                           300    miR-148b      2 \[[@B34], [@B35]\]                           380
  miR-34a                                                                          2 \[[@B20], [@B25]\]                           699    miR-29c       2 \[[@B25], [@B52]\]                           234
  miR-192                                                                          2 \[[@B29], [@B30]\]                           342    miR-29a       2 \[[@B25], [@B26]\]                           154

###### 

The pooled associations between different subgroups and prognosis of patients with NSCLC.

  Subgroup               Number of patients   Number of studies   HR (95% CI)         *P* value   Heterogeneity   
  ---------------------- -------------------- ------------------- ------------------- ----------- --------------- ---------
  Overall effect         5553                 32                  1.59 (1.39--1.82)   \<0.001     84.97%          \<0.001
  *MicroRNAs*                                                                                                     
  miR-21                 2025                 10                  1.95 (1.40--2.72)   \<0.001     88.05%          \<0.001
  miR-155                2047                 9                   1.33 (0.87--2.04)   \<0.001     73.27%          \<0.001
  miR-*let*-7            1239                 4                   1.94 (0.87--4.32)   0.101       87.59%          \<0.001
  miR-148a               377                  2                   2.33 (0.80--6.71)   0.117       57.92%          0.123
  miR-148b               380                  2                   2.28 (1.64--3.17)   \<0.001     0.00            0.749
  *miRNA assay method*                                                                                            
  ISH                    750                  4                   1.05 (0.58--1.87)   0.870       75.51%          0.007
  Microarray/qRT-PCR     4803                 28                  1.63 (1.42--1.87)   \<0.001     85.49%          \<0.001
  *Analysis type*                                                                                                 
  Multivariate           4785                 28                  1.54 (1.35--1.76)   \<0.001     84.81%          \<0.001
  Univariate             768                  4                   2.29 (1.02--5.12)   0.043       72.34%          0.013
  *Source of miRNA*                                                                                               
  Paired Tissue          3999                 20                  1.67 (1.39--1.99)   \<0.001     83.98%          \<0.001
  Blood                  611                  4                   1.73 (1.13--2.65)   0.012       68.02%          0.025
  *Patient origin*                                                                                                
  Asia                   3432                 20                  2.05 (1.66--2.53)   \<0.001     78.85%          \<0.001
  Europe                 662                  6                   1.24 (1.05--1.47)   0.011       61.28%          0.006
  USA                    1439                 6                   2.26 (1.81--2.83)   \<0.001     0.00            0.946

ISH: *in situ* hybridization; qRT-PCR: quantitative real-time polymerase chain reaction; HR: hazard ratio; CI: confidence intervals.

[^1]: Academic Editor: Marco Tomasetti
